Publicacións en colaboración con investigadores/as de University of Oxford (9)

2024

  1. Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4

    Journal of Cardiac Failure

2023

  1. Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

    Journal of the American College of Cardiology, Vol. 81, Núm. 1, pp. 34-45

2021

  1. Stress echo 2030: The novel ABCDE-(FGLPR) protocol to define the future of imaging

    Journal of Clinical Medicine, Vol. 10, Núm. 16

2016

  1. Endolysosomal two-pore channels regulate autophagy in cardiomyocytes

    Journal of Physiology, Vol. 594, Núm. 11, pp. 3061-3077

  2. Human Ischemic Cardiomyopathy Shows Cardiac Nos1 Translocation and its Increased Levels are Related to Left Ventricular Performance

    Scientific Reports, Vol. 6

  3. Metabolic alterations derived from absence of Two-Pore Channel 1 at cardiac level

    Journal of Biosciences, Vol. 41, Núm. 4, pp. 643-658

  4. Protein Inhibitor of NOS1 Plays a Central Role in the Regulation of NOS1 Activity in Human Dilated Hearts

    Scientific Reports, Vol. 6

2012

  1. Increased expression of fatty-acid and calcium metabolism genes in failing human heart

    PLoS ONE, Vol. 7, Núm. 6

2008

  1. Telmisartan, ramipril, or both in patients at high risk for vascular events

    New England Journal of Medicine, Vol. 358, Núm. 15, pp. 1547-1559